Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Parent vs. Induced drug tolerant cells Microarray Analysis

ABSTRACT: WM164 BRAF mutant Melanoma cells were treated with 500nM PLX4032 for 16 days and their gene expression was compared to parent cells kept in DMSO.

ORGANISM(S): Homo sapiens

PROVIDER: GSE54711 | GEO | 2014/02/06

SECONDARY ACCESSION(S): PRJNA237480

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Parent vs. Induced drug tolerant cells Microarray Analysis

Project description:WM164 BRAF mutant Melanoma cells were treated with 500nM PLX4032 for 16 days and their gene expression was compared to parent cells kept in DMSO. WM164 treated and untreated cells were kept in triplicate and the mRNA from individual samples were isolated independently for analysis.

2014-02-06 | E-GEOD-54711 | biostudies-arrayexpress

WM164 BRAF mutant Melanoma cells were treated with 500nM PLX4032 for 60 days and their gene expression was compared to parent cells exposed to a corresponding concentration of DMSO.

Project description:WM164 BRAF mutant Melanoma cells were treated with 500nM PLX4032 for 60 days and their gene expression was compared to parent cells exposed to a corresponding concentration of DMSO.

| PRJNA561544 | ENA

Epigenome analysis of Control and PLX4032 Resistant Clones with EPIC array.

Project description:Genome wide DNA methylation profiling of control and PLX4032 resistant clones to identify resistance-associated methylome alternations, and to integrate with transcriptome analysis. Results provide insight into clonal epigentic adaption of PLX4032 resistance in BRAF V600E melanoma.

2020-09-20 | GSE137452 | GEO

A new ALK isoform transported by extracellular vesicles confers drug resistance to vemurafenib in A375 melanoma cells

Project description:Despite the successful use of drugs targeting the MAPK signaling pathway and immunotherapy in melanoma, the majority of patients with metastatic disease still undergo disease progression indicating a gradual development of therapy resistance. In the present study, microarray analyses were performed on BRAF inhibitor sensitive melanoma cells A375 and corresponding vemurafenib (PLX4032) - resistant cells A375_X1 to describe changes in the transcriptome that might play a role in drug resistance. For each cell line the microarray experiment was performed in duplicates.

2019-02-28 | E-MTAB-6596 | biostudies-arrayexpress

Transcriptomic Analysis of Control and PLX4032 Resistant Clones with RNA Sequencing

Project description:NGS-derived transcriptome profiling (RNA-seq) of control and PLX4032 resistant clones to identify resistance-associated gene-expression changes and pathway enrichments, and to integrate with exome and methylome analysis. Results provide insight into PLX4032 resistance in BRAF V600E melanoma.

2020-09-20 | GSE137309 | GEO

RNA-seq of zebrafish ZMEL1 melanoma cells versus BRAF inhibitor resistant ZMELR1 melanoma cells

Project description:We report how the zebrafish melanoma cell line ZMEL1 changes after 4 month exposure to the BRAF inhibitor PLX4032 (1uM)

2017-01-09 | GSE93299 | GEO

Trascriptional profile of BRAF inhibitor-resistant SKMEL28 and WM3248 melanoma cells and changes upon YAP/TAZ siRNA knockdown

Project description:The activation of transcriptional coactivators YAP and its paralog TAZ has been shown to promote resistance to anti-cancer therapies. YAP/TAZ activity is tightly coupled to actin cytoskeleton architecture. However, the influence of actin remodeling on cancer drug resistance remains largely unexplored. Here, we report a pivotal role of actin remodeling in YAP/TAZ-dependent BRAF inhibitor resistance in BRAF V600E mutant melanoma cells. Melanoma cells resistant to BRAF inhibitor PLX4032 exhibit an increase in actin stress fiber formation, which appears to promote the nuclear accumulation of YAP/TAZ. Knockdown of YAP/TAZ overcomes PLX4032 resistance, whereas overexpression of constitutively active YAP induces resistance. Moreover, inhibition of actin polymerization and cytoskeletal tension in melanoma cells suppresses both YAP/TAZ activation and PLX4032 resistance. Our siRNA library screening identifies actin dynamics regulator TESK1 as a novel vulnerable point of the YAP/TAZ-dependent resistance pathway. These results suggest that inhibition of actin remodeling is a promising synthetic lethal strategy to suppress resistance in BRAF inhibitor therapies.

2015-11-18 | GSE68599 | GEO

Gene expression profiling in melanoma cell lines treated with THZ531 or DMSO

Project description:RNA seq of BRAF-mutated melanoma cell lines (A375 and Colo829) treated with CDK12 inhibitor (THZ531, 500nM) for 6 hours

2022-10-06 | GSE184734 | GEO

Expression data from melanoma cell lines

2010-11-26 | GSE24862 | GEO

Expression data from melanoma cell lines

Project description:Differential gene expression analysis of parental and resistant sub-lines of melanoma cell lines treated or untreated with PLX4032 Using microarray we sought to obtain a genome-wide profile of differentially expressed genes in parental melanoma cell lines and resistant sub-lines in response to PLX4032 vs DMSO control treatment. Representative parental melanoma cell lines and resistant sub-lines were treated with PLX4032 at 1 uM or DMSO control for 6h. Total RNA was extracted and cDNAs were generated and hybridized onto GeneChip Human Gene 1.0 ST Arrays (Affymetrix).

2010-11-26 | E-GEOD-24862 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data